(Q48886048)

English

Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis

scientific article published in May 2005

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

secondary progressive multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Peter Rieckmann

1

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

N Kruse

2

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

L Nagelkerken

3

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

K Beckmann

4

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

D Miller

5

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

C Polman

6

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

F Dahlke

7

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

K V Toyka

8

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

H P Hartung

9

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

S Stürzebecher

10

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

252

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

5

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

526-533

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0681-7

21 January 2018

Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0681-7

21 January 2018

Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0681-7

21 January 2018

Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-beta directly influences monocyte infiltration into the central nervous system.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological indicators of disease activity and prognosis in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-? therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fas(t) track to apoptosis in MS: TNF receptors may suppress or potentiate CNS demyelination

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15895275

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-005-0681-7

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/15895275

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48886048&oldid=2212798546"